Drug Profile
MCS 8
Latest Information Update: 11 Oct 2021
Price :
$50
*
At a glance
- Originator Health Ever Bio-Tech
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Prostate cancer
Most Recent Events
- 11 Oct 2021 MCS-8 is still in phase II trials for Prostate cancer in Taiwan (Health Ever Biotech pipeline, October 2021)
- 05 Sep 2018 MCS-8 is still in phase II trials for Prostate cancer in Taiwan (Health Ever Biotech pipeline, September 2018)
- 04 Nov 2015 Health Ever Biotech initiates enrolment in a phase II trial for Prostate cancer (Prevention) in Taiwan